Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 180
Filter
2.
Nat Commun ; 12(1): 304, 2021 01 12.
Article in English | MEDLINE | ID: mdl-33436631

ABSTRACT

Skeletal muscle conveys several of the health-promoting effects of exercise; yet the underlying mechanisms are not fully elucidated. Studying skeletal muscle is challenging due to its different fiber types and the presence of non-muscle cells. This can be circumvented by isolation of single muscle fibers. Here, we develop a workflow enabling proteomics analysis of pools of isolated muscle fibers from freeze-dried human muscle biopsies. We identify more than 4000 proteins in slow- and fast-twitch muscle fibers. Exercise training alters expression of 237 and 172 proteins in slow- and fast-twitch muscle fibers, respectively. Interestingly, expression levels of secreted proteins and proteins involved in transcription, mitochondrial metabolism, Ca2+ signaling, and fat and glucose metabolism adapts to training in a fiber type-specific manner. Our data provide a resource to elucidate molecular mechanisms underlying muscle function and health, and our workflow allows fiber type-specific proteomic analyses of snap-frozen non-embedded human muscle biopsies.


Subject(s)
Adaptation, Physiological , Exercise , Freeze Drying , Muscle, Skeletal/metabolism , Muscle, Skeletal/physiology , Proteomics , Biomarkers/metabolism , Biopsy , Glucose/metabolism , Humans , Mitochondria/metabolism , Muscle Fibers, Fast-Twitch/metabolism , Muscle Fibers, Skeletal/metabolism , Muscle Fibers, Slow-Twitch/metabolism , Principal Component Analysis , Proteome/metabolism
3.
Pharmacopsychiatry ; 48(7): 274-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26529118

ABSTRACT

INTRODUCTION: Electroconvulsive treatment (ECT) is an effective treatment for severe depression but carries a risk of relapse in the following months. METHODS: Major depressive disorder patients in a current episode attaining remission from ECT (17-item Hamilton Depression Rating Scale (HAM-D17) score≤9) received randomly escitalopram 10 mg, 20 mg, 30 mg or nortriptyline 100 mg as monotherapies and were followed for 6 months in a multicentre double-blind set-up. Primary endpoint was relapse (HAM-D17≥16). RESULTS: As inclusion rate was low the study was prematurely stopped with only 47 patients randomised (20% of the planned sample size). No statistically significant between-group differences could be detected. When all patients receiving escitalopram were compared with those receiving nortriptyline, a marginal superiority of nortriptyline was found (p=0.08). One third of patients relapsed during the study period, and one third completed. DISCUSSION: Due to small sample size, no valid efficacy inferences could be made. The outcome was poor, probably due to tapering off of non-study psychotropic drugs after randomisation; this has implications for future study designs. ClinicalTrials.gov Identifier: NCT00660062.


Subject(s)
Antidepressive Agents/therapeutic use , Citalopram/therapeutic use , Depressive Disorder, Major/therapy , Electroconvulsive Therapy , Nortriptyline/therapeutic use , Adult , Aged , Antidepressive Agents/administration & dosage , Citalopram/administration & dosage , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/prevention & control , Double-Blind Method , Female , Humans , Male , Middle Aged , Nortriptyline/administration & dosage , Secondary Prevention , Treatment Outcome
4.
Clin Pharmacol Ther ; 92(1): 72-9, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22588605

ABSTRACT

Treatment with some types of antidepressants has been associated with sudden cardiac death. It is unknown whether the increased risk is due to a class effect or related to specific antidepressants within drug classes. All patients in Denmark with an out-of-hospital cardiac arrest (OHCA) were identified (2001-2007). Association between treatment with specific antidepressants and OHCA was examined by conditional logistic regression in case-time-control models. We identified 19,110 patients with an OHCA; 2,913 (15.2%) were receiving antidepressant treatment at the time of OHCA, with citalopram being the most frequently used type of antidepressant (50.8%). Tricyclic antidepressants (TCAs; odds ratio (OR) = 1.69, confidence interval (CI): 1.14-2.50) and selective serotonin reuptake inhibitors (SSRIs; OR = 1.21, CI: 1.00-1.47) were both associated with comparable increases in risk of OHCA, whereas no association was found for serotonin-norepinephrine reuptake inhibitors/noradrenergic and specific serotonergic antidepressants (SNRIs/NaSSAs; OR = 1.06, CI: 0.81-1.39). The increased risks were primarily driven by: citalopram (OR = 1.29, CI: 1.02-1.63) and nortriptyline (OR = 5.14, CI: 2.17-12.2). An association between cardiac arrest and antidepressant use could be documented in both the SSRI and TCA classes of drugs.


Subject(s)
Antidepressive Agents , Citalopram/adverse effects , Death, Sudden, Cardiac/etiology , Nortriptyline/adverse effects , Out-of-Hospital Cardiac Arrest/chemically induced , Aged , Antidepressive Agents/adverse effects , Antidepressive Agents/classification , Case-Control Studies , Citalopram/administration & dosage , Death, Sudden, Cardiac/epidemiology , Death, Sudden, Cardiac/prevention & control , Denmark , Depression/drug therapy , Female , Humans , Logistic Models , Male , Middle Aged , Nortriptyline/administration & dosage , Odds Ratio , Out-of-Hospital Cardiac Arrest/epidemiology , Risk Assessment , Time Factors
5.
J Affect Disord ; 140(3): 253-9, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22381949

ABSTRACT

OBJECTIVE: To investigate to what extent the primary depression subtype atypical depression can predict differential outcome of the mono-amino-oxidase inhibitor (MAO-I) moclobemide and the tricyclic antidepressant clomipramine in the Danish University Antidepressant Group Study (DUAG). METHODS: In a randomised, double blind trial, a total of 117 patients with major depression were treated over 6 weeks with either 400 mg moclobemide or 150 mg clomipramine. A baseline principal component analysis (PCA) was performed to identify atypical symptoms on the combined depression scales (Hamilton Depression Scale (HAM-D(17)) and the Quantitative Scale for Atypical Depression (QSAD)). The primary outcome scale was the subscale HAM-D(6) which contains the pure items of depression. RESULTS: PCA identified two items with loadings opposite to the other depression items within HAM-D(17) and QSAD, namely increased duration of sleep and increased appetite (atypical neurovegetative symptoms). Patients with a positive score at baseline on these items were classified as having atypical depression. In total 13 patients were classified as having atypical depression. Within this group of patients 8 received clomipramine and 5 patients received moclobemide. At endpoint the moclobemide treated patients had a significantly better response than the clomipramine treated (P=0.036), effect size 1.42, when using HAM-D(6) as outcome. However, in the 104 patients classified as having typical depression clomipramine was superior to moclobemide (P=0.034), effect size 0.47. LIMITATIONS: The number of patients with atypical neurovegetative symptoms was very small and no placebo arm was included. CONCLUSIONS: It is very important to screen for atypical depression (increased duration of sleep/increased appetite) in the acute therapy of patients with major depression. Our results add to the body of evidence that monoamine oxidase inhibitors are superior to tricyclic antidepressants in this sub-group of patients.


Subject(s)
Antidepressive Agents, Tricyclic/therapeutic use , Clomipramine/therapeutic use , Depressive Disorder, Major/diagnosis , Moclobemide/therapeutic use , Monoamine Oxidase Inhibitors/therapeutic use , Depressive Disorder, Major/drug therapy , Double-Blind Method , Female , Humans , Male , Principal Component Analysis
6.
Cell Prolif ; 44(3): 224-33, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21535263

ABSTRACT

OBJECTIVES: The number of germ cells and somatic cells in human embryonic and foetal gonads has previously been estimated by stereological methods, which are time- and labour-consuming with little information concerning cell proliferation. Here, we studied whether flow cytometry could be applied as an easier method, also enabling estimation of the fraction of cells in S or S+G(2)+M (SG(2) M) cell-cycle phases as indicators of cell proliferation. METHODS: Cell suspensions from 35 human embryonic gonads at days 37 to 68 post-conception (pc) were immunomagnetically sorted into C-KIT positive (germ) cells and negative (somatic) cells. They were stained for DNA content and analysed by flow cytometry. S and SG(2) M fractions could be measured for 13 of the female and 20 of the male gonads. The number of cells was estimated using fluorescent reference beads. RESULTS: During the period from 37 to 68 days pc, female germ and somatic cells had a stable S and SG(2) M fractions indicating steady growth of both subpopulations, whereas they decreased in both male germ and somatic cells. The number of germ and somatic cells estimated by flow cytometry was significantly lower than in stereological estimates, suggesting loss of cells during preparation. CONCLUSIONS: Cell proliferation as indicated by S and SG(2) M fractions could be estimated specifically for primordial germ and somatic cells. Estimation of total number of germ and somatic cells was not feasible.


Subject(s)
Germ Cells/cytology , Alkaline Phosphatase/metabolism , Cell Proliferation , Cell Separation , Female , Flow Cytometry/methods , Fluorescent Dyes/pharmacology , Gonads/cytology , Gonads/embryology , Humans , Immunomagnetic Separation , Male , Pregnancy , Pregnancy Trimester, First , Proto-Oncogene Proteins c-kit/biosynthesis , U937 Cells
7.
Leukemia ; 25(7): 1168-73, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21494256

ABSTRACT

Quantitative PCR (qPCR) for detection of fusion transcripts and overexpressed genes is a promising tool for following minimal residual disease (MRD) in patients with hematological malignancies. Its widespread clinical use has to some extent been hampered by differences in data analysis and presentation that complicate multicenter clinical trials. To address these issues, we designed a highly flexible MRD-reporting software program, in which data from various qPCR platforms can be imported, processed, and presented in a uniform manner to generate intuitively understandable reports. The software was tested in a two-step quality control (QC) study; the first step involved eight centers, whose previous experience with the software ranged from none to extensive. The participants received cDNA from consecutive samples from a BCR-ABL+ chronic myeloid leukemia (CML) patient and an acute myeloid leukemia (AML) patient with both CBFß-MYH11 and WT1 target genes, they conducted qPCR on their respective hardware platforms and generated a series of reports with pre-defined features. In step two, five centers used the software to report BCR-ABL+ MRD in a harmonized manner, applying their recently obtained CML international scale conversion factors. The QC study demonstrated that this MRD-reporting software is suitable for efficient handling of qPCR data, generation of MRD reports and harmonization of MRD data.


Subject(s)
Database Management Systems , Databases, Genetic , Neoplasm, Residual/genetics , Research Report/standards , Reverse Transcriptase Polymerase Chain Reaction/statistics & numerical data , DNA, Complementary/genetics , DNA, Neoplasm/genetics , Europe/epidemiology , Genes, Wilms Tumor , Humans , Information Services , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myeloid, Acute/genetics , Neoplasm, Residual/epidemiology , Oncogene Proteins, Fusion/genetics , Quality Control , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction/methods , Translational Research, Biomedical/methods
9.
Acta Psychiatr Scand ; 118(4): 330-3, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18759806

ABSTRACT

OBJECTIVE: To investigate into the use of the term 'psychotic' as defined by ICD-10 or by the concept of impaired reality testing, among psychiatric staff members. METHOD: Questionnaire investigation using 11 short case vignettes. RESULTS: Responses were received from 266 psychiatric staff members: psychiatrists, nursing staff and psychologists. When using ICD-10, patients were identified as psychotic with a sensitivity ranging from 90% to 55%. Specificity ranged from 60% to 75%. According to the concept of impaired reality testing, all three groups showed a sensitivity of about 60%, whereas specificity ranged from 65% to 50%. The combined use of the terms correlated significantly with responses regarding indication for legal detention for psychiatrists and nursing staff. CONCLUSION: In identifying a patient as 'psychotic' a broad concept of impaired reality testing was widely used particularly in cases with legal issues. Psychotic symptoms, however, were identified with high sensitivity and specificity.


Subject(s)
Psychotic Disorders/diagnosis , Psychotic Disorders/psychology , Surveys and Questionnaires/standards , Denmark , Female , Humans , Male , Middle Aged , Psychotic Disorders/classification , Reality Testing , Sensitivity and Specificity
10.
Br J Cancer ; 95(8): 1114-20, 2006 Oct 23.
Article in English | MEDLINE | ID: mdl-17047657

ABSTRACT

Tissue inhibitor of metalloproteinases-1 (TIMP-1) is one of four inhibitors of the matrix metalloproteinases, which are capable of degrading most components of the extracellular matrix. However, in recent years, TIMP-1 has been recognised as a multifunctional protein, playing a complex role in cancer. In this regard, several studies have demonstrated an antiapoptotic effect of TIMP-1 in a number of different cell types. Since chemotherapy works by inducing apoptosis in cancer cells, we raised the hypothesis that TIMP-1 promotes resistance against chemotherapeutic drugs. In order to investigate this hypothesis, we have established TIMP-1 gene-deficient and TIMP-1 wild-type fibrosarcoma cells from mouse lung tissue. We have characterised these cells with regard to TIMP-1 genotype, TIMP-1 expression, malignant transformation and sensitivity to chemotherapy-induced apoptosis. We show that TIMP-1 gene deficiency increases the response to chemotherapy considerably, confirming that TIMP-1 protects the cells from apoptosis. This is to our knowledge the first study investigating TIMP-1 and chemotherapy-induced apoptosis employing a powerful model system comprising TIMP-1 gene-deficient cells and their genetically identical wild-type controls. For future studies, this cell system can be used to uncover the mechanisms and signalling pathways involved in the TIMP-1-mediated inhibition of apoptosis as well as to investigate the possibility of using TIMP-1 inhibitors to optimise the effect of conventional chemotherapy.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Tissue Inhibitor of Metalloproteinase-1/genetics , Animals , Apoptosis/genetics , Cell Division/drug effects , Cell Division/genetics , Cell Line, Tumor , Cell Survival/drug effects , Cell Survival/genetics , Cell Transformation, Neoplastic/genetics , Cells, Cultured , Cytarabine/pharmacology , DNA Fragmentation/drug effects , Dose-Response Relationship, Drug , Etoposide/pharmacology , Female , Gene Expression/genetics , Genotype , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , Mice, Transgenic , Time Factors , Tissue Inhibitor of Metalloproteinase-1/deficiency , Vincristine/pharmacology
11.
Psychoneuroendocrinology ; 29(7): 917-24, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15177707

ABSTRACT

Moderate to severe depression and mania are associated with a reduced thyroid stimulating hormone (TSH) response to TSH releasing hormone (TRH). Continued reduction of this response after clinical recovery seems indicative of early relapse. The aim of the present study was to test the relationship between mild changes in mood and the TSH response to TRH stimulation in patients with bipolar affective disorder. Nineteen outpatients with bipolar affective disorder were followed prospectively for three years. Every third month, mood symptoms were rated using the 17-item Hamilton Depression Rating Scale (HAMD-17) and the Bech-Rafaelsen Mania Scale (BRMS). A TRH test was performed in connection with each rating session (IV injection of 200 microg TRH), and serum TSH was measured at 0, 20, and 60 min. The maximum TSH response (D-max TSH) and the temporal change in D-max TSH between succeeding rating sessions (DD-max TSH) were determined. Psychometric rating and TRH data were obtained for a total of 198 examinations. The temporal change in mood symptom rating score was negatively correlated with the temporal change in D-max TSH, thus suggesting that increasing severity of mood symptoms was related to a reduced TSH response to TRH stimulation. The temporal change in TSH response to TRH stimulation correlated with the actual score on an overall index of symptom severity. In conclusion, milder fluctuations in mood in bipolar affective disorder seem to correlate with the TSH response to TRH stimulation: Increasing severity of mood symptoms seems to be associated with reduced TSH response.


Subject(s)
Affective Symptoms/blood , Bipolar Disorder/blood , Thyrotropin-Releasing Hormone/administration & dosage , Thyrotropin/blood , Adult , Affective Symptoms/etiology , Aged , Bipolar Disorder/complications , Bipolar Disorder/physiopathology , Follow-Up Studies , Humans , Hypothalamo-Hypophyseal System/physiopathology , Injections, Intravenous , Middle Aged , Neuropsychological Tests , Prospective Studies , Psychometrics , Stimulation, Chemical , Thyroid Function Tests , Thyrotropin/drug effects
12.
Acta Psychiatr Scand Suppl ; (419): 1-22, 2003.
Article in English | MEDLINE | ID: mdl-12974784

ABSTRACT

A subcommittee under the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark have recently developed national guidelines for the psychopharmacological treatment with lithium and antiepileptic drugs, and the present translation aims at contributing to the international discussion on the development of proper guidelines for the treatment of bipolar disorder. Among the antiepileptic drugs, the report deals with valproate, carbamazepine and lamotrigine and to a lesser extent with oxcarbazepine, gabapentin and topiramate. The various drugs will be reviewed, outlining the scientific evidence for mood-stabilizing properties and discussing major side effects, the most important interactions with other drugs and practical use. Special considerations during pregnancy and lactation, during treatment of children and adolescents and during treatment of the elderly will also be presented. Antidepressants and antipsychotics are beyond the scope of the report, but due to the mood-stabilizing properties of at least some of the atypical antipsychotics, these agents will be brought into some focus in connection with the overall treatment guidelines for the different phases of bipolar disorder given at the end of this report.


Subject(s)
Anticonvulsants/therapeutic use , Antimanic Agents/therapeutic use , Bipolar Disorder/drug therapy , Lithium Compounds/therapeutic use , Adolescent , Adult , Aged , Anticonvulsants/adverse effects , Anticonvulsants/pharmacokinetics , Antimanic Agents/adverse effects , Antimanic Agents/pharmacokinetics , Bipolar Disorder/blood , Child , Clinical Trials as Topic , Denmark , Drug Administration Schedule , Drug Interactions , Drug Monitoring , Drug Therapy, Combination , Female , Humans , Lithium Compounds/adverse effects , Lithium Compounds/pharmacokinetics , Male , Middle Aged , Pregnancy
13.
Cytometry ; 44(4): 317-25, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11500848

ABSTRACT

BACKGROUND: Whole-genome amplification of minute samples of DNA for the use in comparative genomic hybridization (CGH) analysis has found widespread use, but the method has not been well validated. METHODS: Four protocols for degenerate oligonucleotide primed polymerase chain reaction (DOP-PCR) and fluorescence labeling were applied to test DNA from normal and K-562 cells. The DNA products were used for CGH analysis. RESULTS: The DOP-PCR-amplified DNA from each protocol produced hybridizations with different qualities. These could be seen primarily as differences in background staining and signal-to-noise ratios, but also as characteristic deviations of normal/normal hybridizations. One DOP-PCR-protocol was further investigated. We observed concordance between CGH results using unamplified and DOP-PCR-amplified DNA. An example of an analysis of an invasive carcinoma of the breast supports the practical value of this approach. CONCLUSIONS: DOP-PCR-amplified DNA is applicable for high- resolution CGH, the results being similar to those of CGH using unamplified DNA.


Subject(s)
DNA Primers/genetics , Nucleic Acid Amplification Techniques/standards , Nucleic Acid Hybridization/methods , Polymerase Chain Reaction/methods , Breast Neoplasms/genetics , DNA, Neoplasm/analysis , Humans , Leukemia, Myeloid/genetics , Nucleic Acid Amplification Techniques/methods , Nucleic Acid Hybridization/genetics , Tumor Cells, Cultured
16.
Anal Cell Pathol ; 23(2): 61-4, 2001.
Article in English | MEDLINE | ID: mdl-11904461

ABSTRACT

We investigated if any change in spatial resolution of comparative genomic hybridization analysis could be detected when using DNA amplified by degenerate oligonucleotide primed PCR (DOP-PCR) as opposed to the use of unamplified DNA. Five DNA samples from B-cell leukemias with small 11q deletions were amplified by DOP-PCR and analysed by means of high resolution comparative genomic hybridization (HR-CGH) for the evaluation of aberration size detection limit. By means of HR-CGH, we found the detection limit of DOP-PCR CGH for deletions to be between 3 Mbp and 7-8 Mbp.


Subject(s)
Chromosomes, Human, Pair 11 , Gene Deletion , Leukemia, B-Cell/genetics , Nucleic Acid Hybridization/methods , DNA, Neoplasm/analysis , Humans , Leukemia, B-Cell/diagnosis , Polymerase Chain Reaction , Sensitivity and Specificity
17.
Curr Protoc Cytom ; Chapter 7: Unit 7.12, 2001 May.
Article in English | MEDLINE | ID: mdl-18770724

ABSTRACT

RNA synthesis has traditionally been investigated by a laborious and time-consuming radiographic method involving incorporation of tritiated uridine. Now a faster non-radioactive alternative has emerged, based on immunocytochemical detection. This method utilizes the brominated RNA precursor bromouridine, which is taken into a cell, phosphorylated, and incorporated into nascent RNA. The BrU-substituted RNA is detected by permeabilizing the cells and staining with certain anti-BrdU antibodies. This dynamic approach yields information complementing that provided by cellular RNA content analysis at a given time and may be of value in studies of cellular activation and gene expression.


Subject(s)
Cell Separation/methods , Flow Cytometry/methods , RNA/analysis , Uridine/analogs & derivatives , Animals , Antigens/biosynthesis , Bromouracil/analogs & derivatives , Cell Membrane/metabolism , Cell Nucleus/metabolism , Gene Expression , Humans , Time Factors , Uridine/analysis , Uridine/pharmacology
18.
Cell Prolif ; 33(6): 381-95, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11101010

ABSTRACT

The microenvironmental changes in the bone marrow, spleen and liver during progression of the transplantable promyelocytic leukaemia in the Brown Norwegian rat (BNML) have been studied. We used flow cytometry to estimate cellular hypoxia and proliferation based on in vivo pulse-labelling with a mixture of 2-nitroimidazole linked to theophylline (NITP) and bromodeoxyuridine (BrdUrd). The leukaemic cells were identified with the RM124 antibody. In rats inoculated with leukaemic cells the fraction of RM124+ cells was significantly increased from day 20 onwards in the spleen and from day 27 in the bone marrow and liver, reaching a level of 65-87% in these organs at day 32. At day 32, the NITP+ fraction of RM124+ cells had increased significantly in the bone marrow and spleen to 88% and 90%, respectively. The corresponding fractions of NITP+ normal cells reached 63% and 65%, respectively. From day 13 to day 32, the DNA-synthesizing (BrdUrd+) fraction of RM124+ cells in the bone marrow decreased significantly from 52% to 25%, and of normal cells from about 20% to 6%. In the bone marrow and spleen at day 27 and 32, the S-phase and G2/M-phase fractions according to DNA content were higher for the NITP+ than for the NITP- cells. This could partly be explained by an impaired cell cycle progression due to hypoxia. Nevertheless, we found indications of leukaemic cells that were simultaneously labelled with NITP and BrdUrd, in the bone marrow and spleen. These latter findings suggest that in contrast to normal cells some of the leukaemic cells can proliferate even during hypoxia, and this subpopulation may consequently renew and expand the leukaemic cell load.


Subject(s)
Leukemia, Myeloid/physiopathology , Oxygen/metabolism , Acute Disease , Animals , Cell Division , Cell Hypoxia , Disease Models, Animal , Disease Progression , Leukemia, Myeloid/metabolism , Rats , Rats, Inbred BN , Tumor Cells, Cultured
19.
Blood ; 96(6): 2219-25, 2000 Sep 15.
Article in English | MEDLINE | ID: mdl-10979969

ABSTRACT

Interaction between CD40 and the CD40 ligand (CD40L) is critical for the survival and proliferation of B cells during immunopoiesis. However, the role of CD40L in the pathogenesis of malignant lymphomas is ambiguous. Primary mantle cell lymphoma (MCL) cells were cultured in the presence of recombinant human CD40L trimer (huCD40LT), and a significant time- and dose-dependent induction of DNA synthesis was observed in thymidine incorporation assays (n = 7, P <.04). The maximal rate of DNA synthesis was reached at huCD40LT doses of 100 ng/mL and above after 4 days of culture, but a significant increase of DNA synthesis was detected already at doses of 1 ng/mL (P =.03). HuCD40LT never inhibited the basal level of DNA synthesis. These findings established 400 ng/mL of huCD40LT for 4 days as standard conditions in the system. Under these conditions, huCD40LT significantly increased the proportion of cells in the S/G(2)/M phases of the cell cycle in 4 of 7 studied cases, while the fraction of apoptotic cells remained unchanged (n = 7). HuCD40LT also induced expression of CD80/B7-1, CD86/B7-2, and CD95/Fas and up-regulated the expression of HLA-DR (n = 6). With the use of bromodeoxyuridine incorporation in triple-color flow cytometric analysis, it was found that huCD40LT induced cell-cycle progression in light chain-restricted cells only, of which a median of 14% (range, 0.5% to 29%; n = 4) returned to G(0/1) phase DNA content after bromodeoxyuridine incorporation, demonstrating completion of at least one cell cycle in the presence of huCD40LT. Thus, primary clonal MCL cells are activated and can proliferate in the presence of huCD40LT as a single agent.


Subject(s)
Lymphoma, Mantle-Cell/pathology , Membrane Glycoproteins/pharmacology , CD40 Antigens/immunology , CD40 Ligand , Cell Division/drug effects , Humans , Lymphoma, Mantle-Cell/immunology , Membrane Glycoproteins/immunology , Recombinant Proteins/immunology , Recombinant Proteins/pharmacology , Tumor Cells, Cultured
20.
Breast Cancer Res Treat ; 60(3): 219-26, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10930109

ABSTRACT

In a consecutive and unselected series of 178 cases of carcinoma in situ of the breast (CIS), comprising both ductal (DCIS) and lobular type (LCIS), and a series of 48 cases of invasive carcinoma (IC) with predominance of DCIS, the association between histopathology, immunohistochemical markers (ER, PgR, MIB-1, c-erbB-2, and p53), and DNA ploidy was investigated, in order to discriminate biologically different groups. In DCIS, significant correlation was shown between large nuclear size and comedonecrosis, both of which showed also strong association to DNA aneuploidy, high proliferation activity, low steroid receptor content, and overexpression of c-erbB-2 and p53 factors that may indicate an aggressive behavior. Small nuclear CIS, whether LCIS or DCIS, on the contrary, were DNA diploid with low proliferation, and no cases showed overexpression of c-erbB-2 and p53. Heterogeneity with respect to the investigated parameters was also a frequent finding that may reflect a development complexity. In IC, comparison of the DCIS and the invasive component showed similar patterns. No significant differences were shown between DCIS without and with invasion. This may indicate that none of the investigated parameters on its own are essential for the event of invasion.


Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/pathology , Carcinoma in Situ/pathology , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/pathology , DNA, Neoplasm/analysis , Neoplasm Proteins/metabolism , Ploidies , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Carcinoma in Situ/genetics , Carcinoma in Situ/metabolism , Carcinoma, Ductal, Breast/genetics , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Lobular/genetics , Carcinoma, Lobular/metabolism , Female , Genetic Markers , Humans , Immunohistochemistry , Mastectomy , Necrosis , Neoplasm Invasiveness
SELECTION OF CITATIONS
SEARCH DETAIL
...